Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2025 revenue €4.07bn (+2.3%); contributive operating margin (CEBIT) 17.9%; net income €398.0m.
Balance sheet figures not captured from release.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving bioMérieux found in HSH's search of the last 24 months.
Data breaches, cyber incidents, regulator action and assurance status.
No confirmed data breaches, cyber incidents or regulator action involving bioMérieux found in HSH's search of the last 24 months. Unverified claims on ransomware leak-site trackers are not included. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Aug 2026: bioMérieux subsidiary BioFire Diagnostics began a Class 2 US recall of specific lots of its BioFire Joint Infection Panel after finding reagent contamination that could cause false positive KPC results.
Contract delivery, go-lives, terminations and disputes.
No notable go-lives, troubled implementations, terminations or customer disputes involving bioMérieux found in HSH's search of the last 24 months.